Cord Blood Expansion and Homing to Improve Engraftment

$534,406P01FY2012CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 39622255 Paper 39033444 Paper 38944797 Paper 38900051 Paper 38238616 Paper 37943204 Paper 37548050 Paper 37038957 Paper 36543374 Paper 36516084 Paper 36175679 Paper 35879429 Paper 35512203 Paper 34914826 Paper 34453686 Paper 34437680 Paper 34267857 Paper 34023569 Paper 34017325 Paper 33986022 Paper 33959279 Paper 33929874 Paper 33717142 Paper 33277313 Paper 33275752 Paper 33232480 Paper 33227136 Paper 32902645 Paper 32779001 Paper 32775304 Paper 32720462 Paper 32023374 Paper 31720305 Paper 31678411 Paper 31292125 Paper 31279695 Paper 30172948 Paper 30076070 Paper 30021768 Paper 29724686 Paper 29616044 Paper 29358941 Paper 29331266 Paper 29075259 Paper 29032062 Paper 29017969 Paper 28506845 Paper 28480300 Paper 28468826 Paper 28428279 Paper 28418996 Paper 28254787 Paper 27919572 Paper 27849617 Paper 27821506 Paper 27692559 Paper 27482888 Paper 27439912 Paper 27378343 Paper 27274983 Paper 27265874 Paper 27265873 Paper 27247137 Paper 27246312 Paper 27207801 Paper 27181409 Paper 27163741 Paper 27129972 Paper 27055866 Paper 26929325 Paper 26920464 Paper 26908740 Paper 26902653 Paper 26779484 Paper 26721209 Paper 26697430 Paper 26648070 Paper 26622998 Paper 26621337 Paper 26484782 Paper 26472485 Paper 26330164 Paper 26250579 Paper 26242737 Paper 26034113 Paper 26030772 Paper 25992361 Paper 25985919 Paper 25925682 Paper 25829402 Paper 25778529 Paper 25711538 Paper 25708219 Paper 25674667 Paper 25632003 Paper 25600436 Paper 25591810 Paper 25566249 Paper 25544748 Paper 25532425

Abstract

Umbilical cord blood (CB) can serve as an alternative graft for patients lacking a matched related donor, yet intrinsically low cell doses leading to delayed engraftment and graft failure severely restrict wider use of this valuable resource. Hence, the central hypothesis of Project 1 is that CB progenitors expanded ex vivo on mesenchymal stem cells (MSCs) will provide more rapid hematopoietic reconsititution, as well as less engraftment failure, than unmanipulated CB cells. Indeed, the CB mononuclear cell/MSC co-culture system we have developed should avoid the significant CD34+ cell losses we experienced in earlier liquid suspension culture studies and, because it provides a surrogate niche for the propagation of CB progenitors, should yield improved CB cell expansion overall. This prediction will be tested in a phase 1 clinical trial in patients undergoing CB transplantation for hematologic malignancies (Aim 1.1), coupled with mechanistic studies to determine if optimal expansion is inhibited by specific CB

View original record on NIH RePORTER →